Article
Endocrinology & Metabolism
Judith Everts-Graber, Daniel Lehmann, John-Patrik Burkard, Benoit Schaller, Brigitta Gahl, HansJoerg Haeuselmann, Ueli Studer, Hans-Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Summary: This study aimed to determine the risk of ONJ in a real-world population, showing a higher incidence rate in patients receiving denosumab therapy compared to those receiving BPs, with previous BP therapy potentially being an additional risk factor for ONJ development.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao
Summary: Multiple myeloma-related bone disease (MBD) is caused by an imbalance in the bone-remodeling process and involves various signaling pathways and molecules. Bisphosphonate and denosumab are currently the standard treatments, while novel bone-modifying therapies are being explored.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Akrivoula Soundia, Danny Hadaya, Yee Chau, Ioannis Gkouveris, Olga Bezouglaia, Sarah Dry, Flavia Pirih, Tara Aghaloo, Sotirios Tetradis
Summary: This study investigated the local application of RANKL to enhance osteoclastic numbers and attachment for improving socket healing in the presence of bisphosphonates. Results showed that RANKL reduced osteonecrosis related to ZA and promoted bone healing. This approach may have clinical implications and improve treatment outcomes for patients on high-dose ZA therapy.
Review
Oncology
Raiza Querrer, Nathalia Ferrare, Nilce Melo, Cristine Miron Stefani, Paula Elaine Diniz dos Reis, Carla Ruffeil Moreira Mesquita, Gabriel Alvares Borges, Andre Ferreira Leite, Paulo Tadeu Figueiredo
Summary: Bisphosphonate-related ONJ and denosumab-related ONJ exhibit differences in imaging characteristics, with the former showing bone sequestra increase, cortical bone lysis, and bone density increase, while the latter showing larger bone sequestra, more frequent periosteal reactions, and mandibular canal enhancement.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Health Care Sciences & Services
Sara Jane Cromer, Kristin M. D'Silva, Elaine W. Yu, Joan Landon, Rishi J. Desai, Seoyoung C. Kim
Summary: The study found that the use of denosumab has surpassed all other bone-directed therapies over the past decade, especially since its approval in 2010. The use of denosumab also showed increasing trends among patients with osteoporosis, malignancies, and recent fractures. However, it is noteworthy that the proportion of using any bone-directed therapy after fractures is low and has declined over time.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
J. Everts-Graber, S. Reichenbach, B. Gahl, H. R. Ziswiler, U. Studer, T. Lehmann
Summary: Patients who received zoledronate after denosumab discontinuation had fewer vertebral fractures, while all subsequent therapies were able to maintain bone mineral density to some extent. Factors such as age, BMI, treatment duration, prior therapy, and BMD gains during denosumab treatment influenced bone mineral density loss, while bone turnover markers correlated with total hip bone loss and treatment duration.
Review
Orthopedics
Chuanjian Yuan, Yanchen Liang, Kai Zhu, Wenpeng Xie
Summary: This study compared the efficacy and safety of teriparatide and denosumab with oral bisphosphonates. The results showed that teriparatide and denosumab were superior to bisphosphonates in increasing bone mineral density and preventing vertebral fractures. Therefore, teriparatide and denosumab may be considered as first-line treatments for glucocorticoid-induced osteoporosis.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
(2023)
Review
Geriatrics & Gerontology
Bridget Boston, Deepak Ipe, Bogdan Capitanescu, Andrei Gresita, Stephen Hamlet, Robert Love, Michael Hadjiargyrou, Chien-Ling Huang, Iulian Nusem, Rodica Ileana Miroiu, Aurel Popa-Wagner, Patrick Hans-Heinrich Warnke, Eugen Bogdan Petcu
Summary: Medication-related osteonecrosis of the jaw (MRONJ) refers to the non-healing jawbone ulcerative-necrotic lesion appearing after dental therapy or minor trauma in patients treated previously with certain medications. Studies have been conducted to explore MRONJ's classification, clinical features, and pathophysiology, as well as its management and new trends in treatment. Conservative therapy may not be effective for severe cases of MRONJ, but new methods that promote local angiogenesis and vascularization show promise in limited trials.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2023)
Review
Medicine, General & Internal
Karel Dandurand, Dalal S. Ali, Aliya A. Khan
Summary: Primary hyperparathyroidism is the most common cause of hypercalcemia in outpatient settings, with most patients being asymptomatic or presenting with non-specific signs. Recent guidelines recommend surgery for patients under 50 years old with significant hypercalcemia, impaired renal function, renal stones, or osteoporosis. Medical interventions, such as optimizing calcium and vitamin D intake and using cinacalcet, can be considered for patients not undergoing surgery. The impact of medical treatment on fracture risk reduction should be a focus of future research.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Hematology
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos
Summary: Bone-modifying therapies, including zoledronic acid and denosumab, are essential for patients with multiple myeloma. Denosumab may offer a survival benefit for patients eligible for autologous transplantation and may be safer for those with renal impairment. Prophylactic measures for hypocalcaemia, renal toxicity, and osteonecrosis of the jaw are important considerations for all bone-modifying agents.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Endocrinology & Metabolism
Judith Everts-Graber, Harald Bonel, Daniel Lehmann, Brigitta Gahl, HansJoerg Haeuselmann, Ueli Studer, Hans-Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Summary: This registry-based study compared the anti-fracture effectiveness of denosumab and bisphosphonates in patients with osteoporosis. Denosumab showed significantly greater risk reduction for vertebral and any fractures compared to alendronate or ibandronate, while no difference in fracture risk reduction was found between zoledronate and denosumab.
OSTEOPOROSIS INTERNATIONAL
(2023)
Article
Chemistry, Multidisciplinary
Joao Andre Correia, Jose Ricardo Ferreira, Miguel Amaral Nunes, Antonio Capelo, Miguel de Araujo Nobre, Francisco Salvado
Summary: VSP and CAD/CAM-customized materials facilitated complete resection of necrotic bone and rigid fixation in MRONJ patients, leading to simplified approach with shorter operative times, reduced morbidity, and predictable results.
APPLIED SCIENCES-BASEL
(2021)
Review
Cell Biology
Zachary S. Bernstein, E. Bridget Kim, Noopur Raje
Summary: Multiple Myeloma is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells in the bone marrow, often leading to bone disease and osteolytic lesions. Treatment options can include osteoclast inhibitory therapies to delay and reduce the risk of skeletal-related events.
Review
Biochemistry & Molecular Biology
Jeng-Shiun Du, Chia-Hung Yen, Chin-Mu Hsu, Hui-Hua Hsiao
Summary: Multiple myeloma is a B-cell neoplasm characterized by clonal plasma-cell proliferation. Treatment with active anti-MM drugs has significantly improved survival and prognosis. Understanding the molecular mechanisms of MM bone disease is crucial in developing effective treatments to prevent skeletal-related events.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Endocrinology & Metabolism
Athanasios D. Anastasilakis, Jessica Pepe, Nicola Napoli, Andrea Palermo, Christos Magopoulos, Aliya A. Khan, M. Carola Zillikens, Jean-Jacques Body
Summary: This study evaluates the differences of MRONJ among different patient categories and provides recommendations on how to mitigate the risk and optimally manage MRONJ. The results indicate that patients with advanced malignancies are at a higher risk for MRONJ compared to those with benign bone diseases, but the overall risk is considerably lower than the benefits of treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Dennis P. Cladis, Elizabeth A. Swallow, Matthew R. Allen, Kathleen M. Hill Gallant, Connie M. Weaver
Summary: The study involved orally administering blueberry polyphenols to ovariectomized rats for 90 days and found that it had little impact on bone mineral density or bone mechanical properties.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Article
Education, Scientific Disciplines
Brownsyne Tucker Edmonds, Alvaro J. Tori, Amy K. Ribera, Matthew R. Allen, Mary E. Dankoski, Sydney Y. Rucker
Summary: The PLUS program is a 2-year initiative that provides professional development and community support for underrepresented in medicine faculty. Through seminars, mentorship, and research-focused activities, scholars receive training and improve their confidence in leadership roles. Survey results show positive outcomes in scholars' career development and interpersonal skills.
Article
Endocrinology & Metabolism
Samantha P. Tippen, Corinne E. Metzger, Elizabeth A. Swallow, Spencer A. Sacks, Joseph M. Wallace, Matthew R. Allen
Summary: The study aimed to investigate the interaction between chronic kidney disease (CKD) and aging on bone structure and mechanical properties. The results showed that aging mice with CKD had significantly higher cortical porosity than young mice, and both structural and mechanical properties were poorer in aging mice.
Article
Nutrition & Dietetics
Jonathan M. Scott, Elizabeth A. Swallow, Corinne E. Metzger, Rachel Kohler, Joseph M. Wallace, Alexander J. Stacy, Matthew R. Allen, Heath G. Gasier
Summary: The study found that high-intensity running did not negatively impact the structure and mechanical properties of the femur and tibia in young growing female rats even in the presence of iron deficiency. Iron deficiency was associated with increased bone resorption markers, while exercise had varying effects on bone formation markers depending on iron status.
BRITISH JOURNAL OF NUTRITION
(2022)
Article
Endocrinology & Metabolism
Elizabeth A. Swallow, Corinne E. Metzger, Christopher L. Newman, Neal X. Chen, Sharon M. Moe, Matthew R. Allen
Summary: This study aimed to assess the effects of reducing parathyroid hormone (PTH) on the development and progression of cortical porosity in CKD. The findings suggest that using etelcalcetide treatment can mitigate the progression of cortical bone changes in an animal model of CKD and limit the development of new pores.
Article
Transplantation
Annabel Biruete, Corinne E. Metzger, Neal X. Chen, Elizabeth A. Swallow, Curtis Vrabec, Erica L. Clinkenbeard, Alexander J. Stacy, Shruthi Srinivasan, Kalisha O'Neill, Keith G. Avin, Matthew R. Allen, Sharon M. Moe
Summary: This study compared the effects of ferric citrate (FC) and intravenous iron sucrose in rats with moderate chronic kidney disease (CKD). The results showed that FC treatment improved phosphorus homeostasis, some iron-related parameters, and the production and cleavage of FGF23. However, neither iron treatment had a significant effect on cardiovascular calcification and bone.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Physiology
Michael P. Liesen, Megan L. Noonan, Pu Ni, Rafiou Agoro, Julia M. Hum, Erica L. Clinkenbeard, John G. Damrath, Joseph M. Wallace, Elizabeth A. Swallow, Matthew R. Allen, Kenneth E. White
Summary: In this study, the researchers investigated the metabolism of iron and phosphate in chronic kidney disease using a mouse model. They found that the protective effect of iron on kidney disease is associated with the loss of FGF23.
PHYSIOLOGICAL REPORTS
(2022)
Article
Critical Care Medicine
Corinne E. Metzger, Josephina Rau, Alexander Stefanov, Rose M. Joseph, Heather C. M. Allaway, Matthew R. Allen, Michelle A. Hook
Summary: Spinal cord injury leads to significant loss of bone, and age and inflammaging can affect skeletal health after SCI. Age and sex also influence bone turnover and serum cytokines. Further research is needed to explore mechanisms and potential therapeutics in different demographics.
JOURNAL OF NEUROTRAUMA
(2023)
Article
Endocrinology & Metabolism
Rachel K. Surowiec, Elizabeth A. Swallow, Stuart J. Warden, Matthew R. Allen
Summary: This study describes a technique to evaluate individual cortical pore dynamics in aging females over one year using HR-pQCT imaging and determines whether formation and expansion of pores would exceed contraction and infilling of pores.
Article
Endocrinology & Metabolism
Corinne E. Metzger, Christopher L. Newman, Samantha P. Tippen, Natalie T. Golemme, Neal X. Chen, Sharon M. Moe, Matthew R. Allen
Summary: Cortical porosity develops in chronic kidney disease (CKD) and varies across different skeletal sites. Higher porosity is seen in flat and irregular bones compared to long bones, as well as in non-weightbearing bones compared to weightbearing bones. There is significant heterogeneity in porosity within skeletal sites and varying correlations between different skeletal sites. These findings highlight the importance of careful site selection in assessing porosity in pre-clinical studies and the potential for fractures at multiple skeletal sites in patients with CKD.
Review
Endocrinology & Metabolism
Sotirios Tetradis, Matthew R. Allen, Salvatore L. Ruggiero
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of antiresorptive medications. The etiology, pathophysiology, and progression of MRONJ remain largely unknown, and current treatment strategies are mostly empirical. This minireview aims to highlight key findings and propose a unifying model for the pathogenesis and progression of MRONJ, as well as identify areas for future research efforts.
Article
Engineering, Environmental
Erin P. Shields, Jonathan D. Krug, William R. Roberson, Stephen R. Jackson, Marci G. Smeltz, Matthew R. Allen, R. Preston Burnette, John T. Nash, Larry Virtaranta, William Preston, Hannah K. Liberatore, M. Ariel Geer Wallace, Jeffrey V. Ryan, Peter H. Kariher, Paul M. Lemieux, William P. Linak
Summary: The destruction of PFAS is crucial for remediating contaminated matrices, but relying solely on DE or DRE to determine their destruction may not fully mineralize PFAS and could result in the release of remaining fluorocarbon portions. The formation of products of incomplete combustion (PICs), including greenhouse gases and potentially hazardous substances, further highlights the need for additional characterization.
ACS ES&T ENGINEERING
(2023)
Article
Endocrinology & Metabolism
Christopher L. Newman, Rachel K. Surowiec, Elizabeth A. Swallow, Corinne E. Metzger, Jieun Kim, Andrew A. Tomaschke, Neal X. Chen, Matthew R. Allen, Joseph M. Wallace, Sharon M. Moe, Yu -Chien Wu, Paul J. Niziolek
Summary: Chronic kidney disease (CKD) is associated with increased risk of hip fractures due to cortical porosity. Current assessment methods have limitations. Ultrashort echo time magnetic resonance imaging (UTE-MRI) may provide an alternative evaluation of cortical porosity. This study aimed to determine if UTE-MRI can detect porosity changes in a rat model of CKD.
Article
Endocrinology & Metabolism
Rachel K. Surowiec, Rosario Saldivar, Ratan K. Rai, Corinne E. Metzger, Andrea M. Jacobson, Matthew R. Allen, Joseph M. Wallace
Summary: The study found that Raloxifene (RAL) and synthetic salmon calcitonin (CAL) can improve bone hydration through non-cell mediated mechanisms, reducing fracture risk, especially in patients with chronic kidney disease. This finding provides a new treatment approach for improving osteoporosis and reducing fracture risk in patients with chronic kidney disease.
Article
Endocrinology & Metabolism
John G. Damrath, Neal X. Chen, Corinne E. Metzger, Shruthi Srinivasan, Kalisha O'Neill, Annabel Biruete, Keith G. Avin, Joseph M. Wallace, Matthew R. Allen, Sharon M. Moe
Summary: Chronic kidney disease-mineral and bone disorder (CKD-MBD) increases cardiovascular calcification and skeletal fragility. Treatments aimed at reducing oxidative stress and parathyroid hormone (PTH) levels can help prevent these complications.
Article
Dentistry, Oral Surgery & Medicine
Jesse G. A. Jones
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Kristina M. Woodis, Luciana Daniela Garlisi Torales, Alejandro Wolf, Allison Britt, Sarah E. Sheppard
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Review
Dentistry, Oral Surgery & Medicine
Balasubramanya Kumar, Srinivasa R. Chandra, Sanjiv Nair, Anjan Kumar Shah
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Review
Dentistry, Oral Surgery & Medicine
Helena Vidaurri de la Cruz, Felipe Velasquez Valderrama, Rosalia Ballona Chambergo
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Kiersten Ricci
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Rishabh Rattan, Nadia Mezghani, Arshad Kaleem, James C. Melville
Summary: Head and neck vascular pathology is a common issue encountered by maxillofacial surgeons. In recent years, laser therapy has gained attention as an adjunctive treatment option for its better accessibility and more predictable outcomes in the intricate and vascular areas of the head and neck.
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Madan Ethunandan
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Jorie Gatts, Srinivasa Chandra, Deepak Krishnan, Kiersten Ricci
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Andrea B. Burke, Chao Dong, Srinivasa R. Chandra
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Jorie Gatts, Srinivasa R. Chandra, Kiersten Ricci
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Srinivasa R. Chandra, Advaith Nair, Sanjiv Nair
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
Article
Dentistry, Oral Surgery & Medicine
Kaylee R. Purpura, Joshua S. Schindler
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
(2024)
